Aguslina Kirtishanti, Siswandono Siswandono, I Ketut Sudiana
email@example.com , firstname.lastname@example.org , email@example.com
Aguslina Kirtishanti1,2, Siswandono Siswandono2*, I Ketut Sudiana3
1Department of Clinical and Community Pharmacy, Faculty of Pharmacy, University of Surabaya, Kalirungkut, Surabaya 60293, East Java, Indonesia.
2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Airlangga University, Airlangga No. 4-6, Surabaya 60286, East Java, Indonesia.
3Department of Pathology, Faculty of Medicine, Airlangga University, Surabaya 60286, East Java, Indonesia.
Volume - 14,
Issue - 3,
Year - 2021
Many of the breast cancer treatments use chemotherapeutic agents in the form of synthetic drugs. Some thiourea and benzoylurea derivatives have been proven to inhibit the proliferation of breast cancer cells. Up until now, the derivation compounds are still being developed. In this study, we synthesized two compounds namely N-(4-bromo)-benzoyl-N'-phenylthiourea and 4-(tert-butyl)-N-benzoylurea. Before the two compounds were synthesized, the prediction of cytotoxic activity in silico was first performed by docking the synthesis compounds with the HER2 receptor (PDB code: 3PP0). The results of the in-silico test are Rerank Score (RS) value using the MVD program (Molegro Virtual Doker). Acyl nucleophilic substitution was carried out to synthesize the compounds. The structure of the synthesized compounds was identified using FTIR, 1H-NMR, 13C-NMR and Mass Spectrometry. In vitro cytotoxic activity was carried out on HER2-positive primary breast cancer cells and produced IC50 values. The results showed that the RS value of N-(4-bromo)-benzoyl-N'-phenylthiourea was smaller (-99.21kcal/mol) than 4-(tert-butyl)-N-benzoylurea (-88.86kcal/mol), meanwhile the RS value of hydroxyurea as a comparison compound which has a urea group and anticancer activity of -34.60kcal/mol. IC50 values of N-(4-bromo)-benzoyl-N’-phenylthiourea and 4-(tert-butyl)-N-benzoylurea were 0.54 mM and 0.61mM respectively. Hydroxyurea had an IC50 value of 11.61mM. It can be concluded that N-(4-bromo)-benzoyl-N’-phenylthiourea was more potent than 4-(tert-butyl)-N-benzoylurea so it can be developed further as an anticancer candidate for HER2-positive breast cancer.
Cite this article:
Aguslina Kirtishanti, Siswandono Siswandono, I Ketut Sudiana. Synthesis and Cytotoxic Activity of N-(4-bromo)-benzoyl-N’phenylthiourea and 4-(tert-butyl)-N-benzoylurea on Primary Cells of HER2-Positive Breast Cancer. Research J. Pharm. and Tech 2021; 14(3):1195-1200. doi: 10.5958/0974-360X.2021.00213.4
Aguslina Kirtishanti, Siswandono Siswandono, I Ketut Sudiana. Synthesis and Cytotoxic Activity of N-(4-bromo)-benzoyl-N’phenylthiourea and 4-(tert-butyl)-N-benzoylurea on Primary Cells of HER2-Positive Breast Cancer. Research J. Pharm. and Tech 2021; 14(3):1195-1200. doi: 10.5958/0974-360X.2021.00213.4 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-3-1
1. International Agency for Research on Cancer, World Health Organization. Available from: https://www.who.int/cancer/ PRGlobocanFinal.pdf, 2-3, 2018 (18 November 2019).
2. Dange VN, Shid SJ, Dr. Magdum CS, Mohite SK. A Review on Breast cancer: An Overview. Asian Journal of Pharmaceutical Research. 2017; 7(1): 49-51
3. Patidar A, Shivhare SC, Ateneriya U, Choudhary S. A Comprehensive Review on Breast Cancer. Asian Journal of Nursing Education and Research. 2012; 2(1): 28-32.
4. Siswandono and Soekardjo, B. Medicinal Chemistry, book 1, Airlangga University Press, Indonesia. 2008; 2nd ed: pp. 255-288, 304-305.
5. Li HQ, Yan T, Yang Y, Shi L, Zhou CF, Zhu HL. Synthesis and structure-activity relationships of N-benzyl-N-(X-2-hydroxybenzyl)-N’-phenylureas and thioureas as antitumor agents. Bioorganic and Medicinal Chemistry. 2010; 18: 305-313.
6. Yang W, Hu Y, Yang YS, Zhang F, Zhang YB, Wang XL, Tang JF, Zhong WQ, Zhu HL. Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skelton as anticancer agents. Bioorganic and Medicinal Chemistry. 2013; 21: 1050-1063.
7. Huang XC, Wang M, Pan YP, Yao GY, Wang HS, Tiang XY, Qin JK, Zhang Y. Synthesis and antitumor activities of novel thiourea α-aminophosphonates from dehydroabietic acid. European Journal of Medicinal Chemistry. 2013; 69: 508-520.
8. Kesuma D, Siswandono, Purwanto BT, Rudyanto M. Synthesis of N-(phenylcarbamothioyl)-benzamide derivatives and their cytotoxic activity against MCF-7 cells. Journal of Chinese Pharmaceutical Sciences. 2018; 27(10): 696-702.
9. Suhud F, Siswandono, Budiati T. Synthesis and activity evaluation of a novel lead compound 1-benzyl-3-benzoylurea as antiproliferative agent. World Journal of Pharmaceutical Sciences. 2015; 3(2): 192-195.
10. Diyah NW, Purwanto BT, Siswandono. Synthesis, molecular docking and antitumor activity of N, N’-carbonylbis(N-ethylbenzamide). World Journal of Pharmaceutical Sciences. 2013; 3(7): 1324-1329.
11. Diyah NW, Ekowati J, Siswandono. Synthesis and Antitumor Activity Evaluation of N, N’-dibenzoyl-N, N’-diethylurea Against Human Breast Cancer Cell Line (MCF-7). International Journal of Pharmacy and Pharmaceutical Sciences. 2014; 6(2): 315-318.
12. Diyah NW, Siswandono, Hardjono S, Purwanto BT. Molecular Modeling and Quantitative Structure Relationship - Cytotoxic Activity of Benzoilurea Derived as Antitumor. Berkala Ilmiah Kimia Farmasi. 2013; 2(2): 20-27.
13. Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Gugliotta L, Harrison C, Hasselbalch H, Lengfelder E, Reilly JT, Michiels JJ, Barbui T. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Bioorganic and Medicinal Chemistry Letters. 2009; 19: 755–758.
14. Sindhu TJ, Arathi KN, Akhila Devi, Aswathi TA, Noushida M, Midhun M, Sajil Saju Kuttiyil. Synthesis, Molecular Docking and Antibacterial Studies of Novel Azole derivatives as Enoyl ACPReductase Inhibitor in Escherichia coli. Asian Journal of Research in Pharmaceutical Sciences. 2019; 9(3): 174-180.
15. Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, Snell G, Jennings A, Iwamoto K, Habuka N, Hirokawa A, Ishikawa T, Tanaka T, Miki H, Ohta Y, Sogabe S. Structural Analysis of The Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein. Journal of Biological Chemistry. 2011; 286(21): 18756-18765
16. Clayden J, Greeves N, Warren S, Wother P. Organic Chemistry, Oxford University Press, New York. 2012; 2nd ed: pp. 279-289.
17. McMurry JM. Fundamental of Organic Chemistry, Brooks/Cole, France. 2011; 7th ed: pp. 349.
18. Murugan V, Revathi S, Sumathi K, Geetha KM, Divekar K. Synthesis of Some 1- [Bis -N, N- (2 - Chloroethyl) Aminoacetyl] - 3,5-Disubstituted -1,2-Pyrazolines as Possible Alkylating Anticancer Agents. Asian Journal of Research in Chemistry. 2010; 3(2): 496-499.
19. Pavia DL, Lampman GM, Kriz GS, James R, Vyvyan JR. Spectroscopy, Brooks/Cole, France. 2009; 4th ed: pp. 851-886.
20. Patil PA, Bhole RP, Chikhale RV, Bhusari KP, Chandekar A. Synthesis of 3, 4-Dihydro-1H-Pyrimidine-5-Carbohydrazide Derivatives and their Pharmacological Screening. Asian Journal of Research in Chemistry. 2010; 3(3): 531-538.
21. Cancer Chemoprevention Research Center Faculty of Pharmacy UGM (CCRC-UGM), Fixed procedure Cytotoxic Test Method MTT. 2012.
22. Kangralkar VA and Kulkarni AR. In Vitro Cytotoxic Activity of Alcoholic Extract of Aristolochia indica. Research Journal of Pharmacy and Technology. 2013; 6(11): 1240-1241.
23. Radhika C, Venkatesham Akena, Venkateshwar Rao J, Sarangapani M. Synthesis and Cytotoxic Activity of New Indole Derivatives. Asian Journal of Research in Chemistry. 2010; 3(4): 965-968.
24. Widiandani T, Arifianti L, Siswandono. Docking, Synthesis, and Cytotoxicity Test Human Breast Cancer Cell Line T47D of N-(Allylcarbamothioyl)benzamide. International Journal of Pharmaceutical and Clinical Research. 2016; 8(5) Suppl: 372-376.
25. Faridi N, Bathaie SZ, Abroun S, Farzaneh P, Karbasian H, Tamanoi F, Mohagheghi MA. Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian women’s breast cancer tumors. Cytotechnology. 2018; 70:625–639.
26. Shi AP, Fan ZM, Ma KW, Jiang YF, Wang L, Zhang KW, Fu SB, Xu N, Zhang ZR. Isolation and characterization of adult mammary stem cells from breast cancer‑adjacent tissues. ONCOLOGY LETTERS. 2017; 14: 2894-2902,
27. Muhamad Nor NA, Halim AS, Ujang Z. Cytotoxicity Screening of Modified Chitosan Derivatives Film on Primary Human Dermal Fibroblasts. Research Journal of Pharmacy and Technology. 2015; 8(3): 242-250.
28. Rathi MA., Meenakshi P, Guru Kumar D, Arul Raj C, Sunitha M, Gopalakrishnan VK. Leaves of Spermacoce hispida as a Novel Cancer Therapeutic – An In Vitro Study. Research Journal of Pharmacy and Technology. 2011; 4(8): 1288-1291.
29. Singh MK, Prathapan A., Nagori K, Ishwarya S, Raghu KG. Cytotoxic and Antimicrobial Activity of Methanolic Extract of Boerhaavia diffusa L. Research Journal of Pharmacy and Technology. 2010; 3(4): 1061-1063.
30. Hinchliffe A. Molecular Modeling for Beginners, John Wiley and Sons Ltd, UK. 2008; 2nd ed.
31. Hardjono S, Widiandani T, Purwanto BT, Nasyanka AL. Molecular Docking of N-benzoyl-N'-(4-fluorophenyl) thiourea Derivatives as Anticancer Drug Candidate and Their ADMET prediction. Research Journal of Pharmacy and Technology. 2019; 12(5): 2160-2166.
32. Brugnoli F, Grassilli S, Al-Qassab Y, Capitani S, Bertagnolo V. CD133 in Breast Cancer Cells: More than a Stem Cell Marker. Journal of Oncology. 2019; 2019: 1-8.
33. Tume L, Paco K, Ubidia-Incio R, Moya J. CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy. Gaceta Mexicana de Oncologia. 2016; 15(1): 22-30.
34. Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in cancers: Overexpression and Therapeutic Implications. Molecular Biology International. 2014; 2014: 1-9.